Lexington, United States
Anagenex, founded in 2019 and headquartered in the United States, is making waves in pharmaceutical innovation by merging ultra high throughput biochemistry with machine learning. With its slogan, "Evolving new small molecule medicines by combining ultra high throughput biochemistry and machine learning," the company is at the forefront of revolutionizing drug discovery methods. This convergence of advanced biochemistry and cutting-edge technology positions Anagenex as a notable contender in the biotech sector.
The company's progress attracted significant investment, most notably a $30.00M Series A investment on 01 June 2022. This funding round saw participation from prominent investors such as Air Street Capital, Lux Capital, Obvious Ventures, Khosla Ventures, Menlo Ventures, and Catalio Capital Management. Such backing underscores the strong belief in Anagenex's potential to pioneer transformative solutions in medicine.
